Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Cristina Astrid Tentori, Caterina Gregorio, Marie Robin, Nico Gagelmann, Carmelo Gurnari, Somedeb Ball, Juan Carlos Caballero Berrocal, Luca Lanino, Saverio D'Amico, Marta Spreafico, Giulia Maggioni, Erica Travaglino, Elisabetta Sauta, Manja Meggendorfer, Lin-Pierre Zhao, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Maria Borin, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Jan Philipp Bewersdorf, Olivier Nibourel, Marina Díaz-Beyá, Andres Jerez, Francisca Maria Hernandez, Kyra Velázquez Kennedy, Blanca Xicoy, Marta Ubezio, Alessia Campagna, Antonio Russo, Gabriele Todisco, Daniele Mannina, Stefania Bramanti, Matteo Zampini, Elena Riva, Marilena Bicchieri, Gianluca Asti, Filippo Viviani, Alessandro Buizza, Benedetta Tinterri, Andrea Bacigalupo, Alessandro Rambaldi, Francesco Passamonti, Fabio Ciceri, Victor Savevski, Armando Santoro, Najla H Al Ali, David A Sallman, Francesc Sole, Guillermo Garcia-Manero, Ulrich Germing, Shahram Kordasti, Valeria Santini, Guillermo Sanz, Wolfgang Kern, Anne Sophie Kubasch, Uwe Platzbecker, Maria Diez-Campelo, Jaroslaw P. Maciejewski, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Amer M. Zeidan, Gastone Castellani, Rami S. Komrokji, Francesca Ieva, Matteo Giovanni Della Porta

Blood (2023) 142 (Supplement 1): 197.

https://doi.org/10.1182/blood-2023-182194

Published: 2023

Journal Articles

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Blood (2022) 140 (Supplement 1): 1121–1124.

https://doi.org/10.1182/blood-2022-163634

Published: 2022

Journal Articles

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Blood (2021) 138 (7): 507–519.

https://doi.org/10.1182/blood.2021011103

Published: 2021

Includes: Supplemental data

Journal Articles

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Nicolas Duployez, Christophe Willekens, Isabelle Plo, Alice Marceau-Renaut, Stéphane de Botton, Laurène Fenwarth, Thomas Boyer, Guillemette Huet, Olivier Nibourel, Christian Rose, Brigitte Nelken, Bruno Quesnel, Claude Preudhomme

Blood (2019) 134 (26): 2414–2416.

https://doi.org/10.1182/blood.2019003206

Published: 2019

Includes: Supplemental data

Journal Articles

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Nico Gagelmann, Anita Badbaran, Rashit Bogdanov, PhD, Olivier Nibourel, Friedrich Stoelzel, MD, Christina Rautenberg, MD, Heiko Becker, MD, Aleksandar Radujkovic, MD, Michael Koldehoff, Prof, MD PhD, Maximilian Christopeit, PhD, Peter Dreger, Jürgen Finke, MD, Guido Kobbe, MD, Uwe Platzbecker, Marie Robin, MD, Dietrich W. Beelen, Nicolaus Kroeger, MD

Blood (2019) 134 (Supplement_1): 1713.

https://doi.org/10.1182/blood-2019-121969

Published: 2019

Journal Articles

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Blood (2018) 132 (Supplement 1): 993.

https://doi.org/10.1182/blood-2018-99-111144

Published: 2018

Journal Articles

Chemotherapy Treatment Doesn't Beneficiate to a Group of Elderly AML Patients with Absence of Complex Karyotype and Circulating Blasts

Berengere Gruson, MD, Magalie Joris, Olivier Nibourel, Véronique Harrivel, MD, Nathalie Cambier, MD, Pauline Lionne, Bachra Choufi, Celine Rodriguez, Cecile Frimat, Isabelle Plantier, MD, Laure Stalnikiewicz, Maxime Bemba, Céline Berthon, MD PhD, Claude Preudhomme, Pierre Morel, MD, Jean-Pierre Marolleau, MD PhD

Blood (2018) 132 (Supplement 1): 2679.

https://doi.org/10.1182/blood-2018-99-116144

Published: 2018

Journal Articles

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Lea Herpe, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3946.

https://doi.org/10.1182/blood.V128.22.3946.3946

Published: 2016

Journal Articles

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

Antony Ceraulo, Aminetou Mint-Mohamed, Delphine Maucort-Boulch, MD PhD, Helene Lapillone, Guy Leverger, MD, Etienne Paubelle, MD PhD, Xavier Thomas, MD PhD, Olivier Nibourel, PharmD, PhD, Claude Preudhomme, MD PhD, Sylvie Castaigne, MD PhD, Hervé Dombret, Lea Herpe, Christine Ragu, PhD, Yves Bertrand, MD PhD, Franck Mortreux, PhD, Eric Wattel, MD PhD

Blood (2016) 128 (22): 3952.

https://doi.org/10.1182/blood.V128.22.3952.3952

Published: 2016

Journal Articles

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

Loïc Renaud, Olivier Nibourel, PharmD, PhD, Celine Berthon, Christophe Roumier, Céline Rodriguez, Cecile Frimat, Catherine Roche-Lestienne, Aline Renneville, MD, Bruno Quesnel, MD PhD, Claude Preudhomme, MD PhD

Blood (2016) 128 (22): 4013.

https://doi.org/10.1182/blood.V128.22.4013.4013

Published: 2016

Journal Articles

NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group

Marie Balsat, MD, Aline Renneville, Xavier Thomas, Alice Marceau, Stéphane De Botton, Olivier Nibourel, Emmanuel Raffoux, Céline Rodriguez, Jean-Michel Cayuela, Sandrine Hayette, Christine Terré, Karine Celli-Lebras, Hervé Dombret, Claude Preudhomme, Nicolas Boissel

Blood (2015) 126 (23): 2581.

https://doi.org/10.1182/blood.V126.23.2581.2581

Published: 2015

Journal Articles

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

Blood (2014) 124 (21): 482.

https://doi.org/10.1182/blood.V124.21.482.482

Published: 2014

Journal Articles

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Blood (2014) 124 (21): 68.

https://doi.org/10.1182/blood.V124.21.68.68

Published: 2014

Journal Articles

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Alice Marceau-Renaut, Meyling Cheok, Nicolas Duployez, Olivier Nibourel, Nathalie Helevaut, Céline Rodriguez, Karine Celli-Lebras, Céline Berthon, Guy Leverger, MD, Nicolas Boissel, MD PhD, Christine Terré, Xavier Thomas, Sylvie Castaigne, Herve Dombret, Claude Preudhomme, PharmD, PhD, Aline Renneville

Blood (2014) 124 (21): 2360.

https://doi.org/10.1182/blood.V124.21.2360.2360

Published: 2014

Journal Articles

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Blood (2014) 124 (21): 2374.

https://doi.org/10.1182/blood.V124.21.2374.2374

Published: 2014

Journal Articles

Epidemiology of Adults AML in Nord-Pas De Calais and Picardy

Blood (2014) 124 (21): 2281.

https://doi.org/10.1182/blood.V124.21.2281.2281

Published: 2014

Journal Articles

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Blood (2014) 124 (21): 2324.

https://doi.org/10.1182/blood.V124.21.2324.2324

Published: 2014

Journal Articles

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Blood (2014) 124 (21): 2327.

https://doi.org/10.1182/blood.V124.21.2327.2327

Published: 2014

Journal Articles

Genomic Landscape of CXCR4 Mutations in Waldenstrom's Macroglobulinemia

Stephanie Poulain, Christophe Roumier, Emmanuelle Doye, Martin Figeac, Aurélie Caillault, Sandrine Geffroy, Olivier Nibourel, PhD, Frederic Lepretre, Agnes Daudignon, Sabine Tricot, MD, Patrick Duthilleul, Claude Preudhomme, PharmD, PhD, Xavier Leleu, MD

Blood (2014) 124 (21): 1627.

https://doi.org/10.1182/blood.V124.21.1627.1627

Published: 2014

Journal Articles

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Remy Dulery, MD, Olivier Nibourel, PhD, Vincent Elsermans, David Beauvais, MD, Arthur Simonnet, MD, Jordan Gauthier, MD, Valérie Coiteux, MD, Leonardo Magro, MD, Bruno Quesnel, MD, Claude Preudhomme, Ibrahim Yakoub-Agha, MD PhD

Blood (2014) 124 (21): 1265.

https://doi.org/10.1182/blood.V124.21.1265.1265

Published: 2014

NARROW

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic Syndromes (MDS)

Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

Inherited transmission of the CSF3R T618I mutational hotspot in familial chronic neutrophilic leukemia

Clinical Relevance of Somatic Mutations in Chronic Myelomonocytic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial

Chemotherapy Treatment Doesn't Beneficiate to a Group of Elderly AML Patients with Absence of Complex Karyotype and Circulating Blasts

ABCA3 Expression Predicts Response to Gemtuzumab Ozogamicin in AML

Age and Gemtuzumab Ozogamicin Influence the Prognostic Impact of TET2 Expression and Splicing in Intensively Treated Patients with Acute Myeloid Leukemia

De Novo and Secondary Acute Myeloid Leukemia, Real World Data on Outcomes from the French Nord-Pas-De-Calais Picardie Acute Myeloid Leukemia Observatory

NPM1 Minimal Residual Disease As Prognostic and Predictive Factor in Young Adults with Acute Myeloid Leukemia: a Study By the French ALFA Group

Molecular Prognostic Factors in Acute Myeloid Leukemia (AML) Patients Receiving First Line Therapy with Azacytidine (AZA)

TET2 Exon 2 Skipping Confers Sensitivity to AraC and Is an Independent Favorable Prognostic Factor in AML Patients Treated with Intensive Chemotherapy

Prognostic Analysis of GATA2 Mutations in CEBPA -Mutated Acute Myeloid Leukemia

Results of the “Evaluation of NGS in AML-Diagnostics (ELAN)” Study – an Inter-Laboratory Comparison Performed in 10 European Laboratories

Epidemiology of Adults AML in Nord-Pas De Calais and Picardy

Skipping of ATP-Binding Cassette Transporter A3 Exon 19 in AML Cells Is an Independent Prognostic Factor in Patients with Normal Cytogenetics

Inversely to DNMT3A, IDH1/IDH2 Are Good Targets for Monitoring Minimal Residual Disease (MRD) in Acute Myeloid Leukemia (AML): A Pilot Study of the ALFA Group

Genomic Landscape of CXCR4 Mutations in Waldenstrom's Macroglobulinemia

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only